Abaxis says FDA approved C-Reactive Protein test for infections and inflammatory diseases
By APThursday, January 21, 2010
Abaxis says FDA clears new infection test
UNION CITY, Calif. — Blood analysis systems company Abaxis Inc. said Thursday it received marketing approval for a test designed to detect infections and inflammatory diseases like rheumatoid arthritis.
Abaxis said the Food and Drug Administration cleared its C-Reactive Protein assay, which is designed to run on the company’s Piccolo Xpress system. It said the assay can test for infections, inflammatory diseases, tissue injuries and abnormal cell growth in less than 12 minutes.
The CRP test has been in use in Europe and Asia Pacific for more than six months as part of general health screenings and clinical practice.
In afternoon trading, Abaxis shares fell 96 cents, or 3.8 percent, to $24.14 as the broader market also declined.
